The R-CHOP chemotherapy regimen -- rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine (Oncovin), and prednisone -- has been the standard first-line therapy in diffuse large B-cell ...
SAN DIEGO — Standard therapy for young patients with favorable-prognosis diffuse large B-cell lymphoma (DLBCL) is six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin [hydroxydaunomycin], ...
John Burke, MD, hematologist, Rocky Mountain Cancer Centers, discussed findings of the late-breaking abstract session POLARIX presented at ASH 2021, which compared pola-R-CHP with standard-of-care ...
Please provide your email address to receive an email when new articles are posted on . The regimen conferred a 71% complete response rate among older adults with newly diagnosed DLBCL. Median PFS and ...
Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester ...
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates Compared with some other ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results